Immix Biopharma, Inc
11150 W. Olympic Boulevard
About Immix Biopharma, IncImmix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The team was founded by Vladimir Torchilin, Ph.D., D.Sc. Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University and the former Head of Chemistry Program at Harvard Medical School and Massachusetts General Hospital; Ilya Rachman, an MD, PhD, MBA, physician scientist and clinical researcher; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney and fund manager.
Founders: Ilya Rachman, Sean Senn, and Vladimir Torchilin
CEO: Ilya Rachman
Please click here for clinical trial information.
16 articles with Immix Biopharma, Inc
ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors
Immix Biopharma, Inc. ("ImmixBio") today announced a clinical trial and supply agreement with BeiGene, Ltd. to evaluate the safety, tolerability and efficacy of combining IMX-110 with TME Normalization™ Technology
Immix Biopharma, Inc. today announced that Galit Lahav, PhD, Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School has joined its Scientific Advisory Board.
ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory Board
Immix Biopharma, Inc. today announced that George W. Sledge, MD, Professor of Medical Oncology and former Chief of Medical Oncology at Stanford University Medical Center has joined its Scientific Advisory Board.
Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)™ for oncology and inflammation, today announced that world-renown institutional asset manager and well-recognized investment leader Jane Buchan, PhD has joined the Company's Board of Directors.
ImmixBio Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Immix Biopharma, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering ("IPO") of its common stock.
Immix Biopharma, Inc. today announced that accounting and financial expert Helen C. Adams , CFA has joined the Company's Board of Directors.
Immix Biopharma, Inc. today announced that Gabriel Morris has joined its leadership team as Chief Financial Officer and a member of the Board of Directors.
Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors
Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States
Mesa Verde managing director, Carey Ng, PhD, MBA, also joined the Board.
Immix Biopharma, Inc announced that it received a letter from the FDA authorizing it to proceed with expanding its phase 1b/2a clinical trial of IMX-110 to the United States under an IND.
Immix Biopharma, Inc announced today positive interim results from its ongoing phase 1b/2a study testing IMX-110 in advanced solid tumors. Immix observed Stable Disease at cohort (dose-level) 2 in a middle-aged male with stage IV colorectal cancer that was refractory to radiation therapy, chemotherapy and immunotherapy.
Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study
Immix Biopharma, Inc. announced that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110.
Immix Biopharma is proud to announce it has received Human Research Ethics Committee (IRB) approval to begin a Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Participants with Advanced Solid Tumors.
Immix Biopharma Release: Pioneering Cancer Startup Closes Series A To Take Lead Candidate Through Phase 1B Clinical Trials
Immix Biopharma Accelerates Financing Efforts To Extend Its Cancer Therapeutic Platform After Receiving Positive Stability Data For Lead Candidate